Venous thromboembolism and lung cancer: a review

Abstract


 
 
 
 Venous thromboembolism (VTE) is a common complication of malignancies and epidemiological studies suggest that lung cancer belonged to the group of malignancies with the highest incidence rates of VTE. Risk factors for VTE in lung cancer patients are adenocarcinoma, NSCLC in comparison with SCLC, advanced disease, pneumonectomy, chemotherapy including antiangiogenic therapy. Other risk factors are pretreatment platelet counts and increased release of TF-positive microparticles. Elevated D-dimer levels do not necessarily indicate an increased risk of VTE but have been shown to be predictive for a worse clinical outcome in lung cancer patients. Mechanisms responsible for the increase in venous thrombosis in patients with lung cancer are not understood. Currently no biomarker is recognized as a predictor for VTE in lung cancer patients. Although several clinical trials have reported the efficacy of antithrombotic prophylaxis in patients with lung cancer who are receiving chemotherapy, further trials are needed to assess the clinical benefit since these patients are at an increased risk of developing a thromboembolism.
 
 
 

Timing and Risk Factors Associated With Venous Thromboembolism After Lung Cancer Resection

“…As a result, we believe that our data are representative of the prevalence of VTE in thoracic surgical patients and provide an appropriate foundation from which guidelines may be revised. The ICD-9 and ICD-10 diagnosis codes used to identify patients are not histologically or cancer stage specific, and therefore this study is unable to account for the impact of stage on VTE risk [30]. Finally, the impact of known perioperative risk factors in thoracic surgical patients, such as pulmonary function test results, long-term smoking history, and preoperative performance status, is not available in the ACS NSQIP dataset.…”

Development and Validation of a Risk Score for Prediction of Venous Thromboembolism in Patients With Lung Cancer

“…Several risk factors for cancer-related VTE have been identified, including cancer type, age, gender, bed rest, central venous catheter (CVC), anticancer treatment, and so on. 7,9 Although several VTE risk score system have been published in the recent years, they rely on biochemical predictors or are not lung cancer specific and thus provide limited clinical benefit. [10][11][12] Hence, the aim of this retrospective cohort study was to study clinical predictors of VTE in Chinese patients with lung cancer and to develop a scoring system to provide a reliable estimate of VTE risk.…”

Effect of Huisheng oral solution on coagulation function in perioperative period in patients with primary lung cancer

“…Current main treatments for cancer include surgery, chemotherapy, radiotherapy, and targeted therapy. All these treatments may increase the risk of VTE in patients (4)(5)(6)(7)(8)(9)(10)(11). In recent years, researchers have attempted to study the correlation between lung cancer and abnormal coagulation as well as the prevention and treatment of abnormal coagulation in lung cancer patients.…”